Please note that the following presentations contain financial projections and other forward-looking statements that are specific to the date of the presentations – May 22, 2013 – and should not be considered current after that date. 1 2013 Analyst Meeting May 22, 2013 2 Safe Harbor / Non-GAAP Measures Various remarks that we may make in the following presentations about the company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our Form 10-Q for the quarter ended March 31, 2013, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investors” section of our website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; the effect of healthcare reform legislation; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to the pending acquisition of Life Technologies may not materialize as expected. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. During these presentations, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP, including adjusted EPS, adjusted gross margin, adjusted operating margin, adjusted ROIC, adjusted ROE and free cash flow. Definitions of these non-GAAP financial measures and, for historical periods, a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in the appendix to these presentations. Please note that the attached presentations contain financial projections and other forward-looking statements that are specific to the date of the presentations – May 22, 2013 – and should not be considered current after such date. 3 Agenda Marc Casper Intensely Focused on Our Customers to Drive Growth President and CEO Pete Wilver Creating Shareholder Value Chief Financial Officer Alan Malus Innovating to Solve New Customer Challenges President, Analytical Technologies Andy Thomson Innovating to Improve Human Health and Drive Growth President, Specialty Diagnostics Ed Pesicka Partnering with Customers to Deliver a Unique Value Proposition President, Customer Channels Syed Jafry President, Asia-Pacific Strengthening Our Global Presence to Accelerate Growth & Emerging Markets Marc Casper Summary and Q&A 4 Intensely Focused on Our Customers to Drive Growth Marc Casper President and Chief Executive Officer 2013 Analyst Meeting May 22, 2013 We Are the World Leader in Serving Science Global Scale • 39,000 employees in 40 countries • $13 billion in annual revenues • Unparalleled commercial reach • Ranked 220 on Fortune 500 Unmatched Depth • Innovative technologies • Applications expertise Industry-leading Brands • Lab productivity partner 6 Our Unique Scale and Depth of Capabilities Leading portfolio of specialty diagnostic Specialty tests to improve Diagnostics patient care Segment Premier supplier to 23% enable laboratory productivity and Laboratory accelerate innovation Products and Services Revenue Segment 46 % Analytical Technologies Segment 31 % Most comprehensive technology portfolio for both research and applied markets 7 Note: Revenue based on LTM through Q1 2013. Percentages shown are before inter-company eliminations. Significant and Growing Addressable Markets Specialty Diagnostics ~$20B m arket 4 - 6% gr owth Laboratory Products and Addressable Services Market ~$30B m arket 3-5% long-term 1 - 3% g rowth Analytical growth Technologies ~$3 3B market 4 - 6 % growth 8 Strong Track Record of Financial Performance Revenue Adjusted Operating Adjusted Adjusted ($B) Income ($B) EPS ($) ROIC 9.3% $12.5 $4.94 $2.4 8.0% $9.4 $1.6 $2.55 2007 2012 2007 2012 2007 2012 2007 2012 9 Our Vision for 2020 Advancing our position as the industry leader Strengthening our premier brands to be the most powerful in our industry Developing innovative technologies to profoundly benefit life sciences, healthcare and the environment Significantly increasing our presence in Asia-Pacific and emerging markets Being recognized as one of the world’s most admired companies Delivering consistent and strong earnings growth 10